Project Grant K99AI191911
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $147,486 to Weill Medical College of Cornell University to conduct research on identifying metabolic profiles in HIV-infected CD4+ T-cells that are resistant to cytotoxic T-lymphocyte (CTL) elimination. The goal is to better understand mechanisms of HIV reservoir persistence during antiretroviral therapy, which is a key barrier to curing HIV...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $806,208 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Weill Medical College of Cornell University. The project, titled "Spatial Omics to Understanding HBV Control in People with HIV Coinfection," will leverage cutting-edge spatial proteomic and transcriptomic technologies to analyze the impact of HIV-related immune suppression and restoration on the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing the HIV-1 viral reservoirs that persist even under antiretroviral therapy (ART). The 2-year project aims to identify the cellular sources and genetic diversity of the HIV-1 reservoirs, as well as study the sources and characteristics of the residual viremia...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $824,331 Project Grant to Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The research aims to improve understanding of the establishment and persistence of latent viral reservoirs in HIV-infected individuals, particularly the role of naive CD4+ T cells, in...
- This $118,488 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 20, 2025, supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The project aims to identify genetic mutations in the CCR5 and CXCR4 co-receptors that can prevent HIV entry into CD4 cells while maintaining the central functions of these proteins in hematopoiesis. The research involves...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $238,972 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation for the State University of New York, doing business as Sponsored Projects Services, to study the role of the cellular protein EHD4 in restricting HIV-1 infection. The research aims to determine the mechanism by which EHD4 decreases the infectivity of HIV-1 particles by impacting the incorporation of...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This $243,713 Project Grant awarded on January 27, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research to characterize mechanisms by which HIV-infected macrophages evade antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer (NK) cells. The objective is to determine how infected macrophages, which serve as a physiologically relevant viral reservoir, resist NK cell...
This Project Grant award of $149,389, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to characterize the clonal landscape of the HIV reservoir in CD4 cells. The awardee, Weill Medical College of Cornell University, will isolate and culture pure CD4 HIV reservoir clonal populations to phenotypically, genotypically, and functionally analyze them. This includes evaluating mechanisms of clone persistence and resistance to cytotoxic T-cell killing. The research aims to advance the understanding of the HIV reservoir and inform potential curative strategies. The project period runs from August 11, 2025 to July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $149.4k | 8/11/25 |